Nautilus Biotechnology, Inc. NAUT PHARMA
Company Overview
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.21.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +29.78% |
| 6 Months: | -63.03% |
| 3 Months: | -60.18% |
| 1 Month: | +3.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)41.01 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 76.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NAUT Nautilus Biotechnology, Inc. PHARMA | 0.93 | -2.07 | $118.18M | 0.00% | - | -36.21% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 10.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | 15.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | -5.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 17.10M | 15.47M | 15.42M | 16.12M | 15.76M |
| Operating Income | - | -174.67K | -1.78M | - | - | - | - | - | - | - | - | - | - | - | - | -17.10M | -15.47M | -15.42M | -16.12M | -15.76M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.46M | -13.85M | -13.84M | -14.65M | -14.48M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.03M | -13.57M | -13.78M | -14.70M | -14.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -3.35M | -3.98M | -8.41M | -10.71M | -14.50M | -15.76M | -14.69M | -14.06M | -14.96M | -15.81M | -15.88M | -18.73M | -18.01M | -16.45M | - | -15.03M | -13.57M | -13.78M | -14.70M | -14.47M |
| Diluted EPS | -0.12 | -0.13 | -0.25 | -0.19 | -0.12 | -0.13 | -0.12 | -0.11 | -0.12 | -0.13 | -0.13 | -0.15 | -0.14 | -0.13 | - | -0.12 | -0.11 | -0.11 | -0.12 | -0.11 |
| R&D Expense | 2.75M | 3.32M | 4.83M | 6.38M | 8.24M | 9.66M | 8.86M | 9.57M | 10.88M | 11.91M | 12.00M | 12.93M | 12.44M | 12.29M | 11.54M | 10.39M | 9.61M | - | 9.71M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Net Income | -15.62M | -50.31M | -57.92M | -63.67M | -70.78M | -59.00M |
| Diluted EPS | -0.54 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 |
| R&D Expense | 12.43M | 29.35M | 37.67M | 47.25M | 50.48M | 41.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 85.01M | - | 350.05M | 305.56M | 242.74M | 191.11M |
| Current Assets | - | - | - | - | 187.21M | 176.84M | 132.83M | 105.96M |
| Cash & Equivalents | - | - | 36.61M | - | 114.52M | 19.40M | 27.65M | 12.39M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 6.31M | - | 35.13M | 40.21M | 34.01M | 34.14M |
| Current Liabilities | - | - | 3.02M | - | 6.79M | 9.12M | 7.63M | 7.95M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 30.33M | 34.63M | 30.48M | 30.02M |
| Total Equity | -14.51M | 0 | -29.72M | - | 314.92M | 265.35M | 208.73M | 156.97M |
| Shares Outstanding | - | - | - | - | 124.87M | 125.07M | 126.11M | 126.47M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.00M | -39.24M | -45.81M | -51.71M | -59.15M | -50.70M |
| Investing Cash Flow | -25.28M | -138.96M | -25.74M | -43.73M | 66.25M | 35.22M |
| Financing Cash Flow | 75.90M | 327.45M | 562.00K | 368.00K | 1.14M | 214.00K |
| Capital Expenditure | -921.00K | -2.27M | -2.32M | -2.44M | -2.12M | -1.28M |
| Free Cash Flow | -14.92M | -41.51M | -48.13M | -54.15M | -61.27M | -51.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 52.6% | - | -18.4% | -24.0% | -33.9% | -37.6% |
| ROCE % | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Perceptive Advisors Llc | 9.14% | 11.63M | $11.24M |
| 2 | a16z Capital Management, L.L.C. | 7.12% | 9.06M | $8.75M |
| 3 | Cercano Management Llc | 5.64% | 7.17M | $6.93M |
| 4 | Blackrock Inc. | 2.11% | 2.69M | $2.60M |
| 5 | Vanguard Capital Management LLC | 2.00% | 2.55M | $2.46M |
| 6 | Comprehensive Financial Management, LLC | 1.73% | 2.21M | $2.13M |
| 7 | Citadel Advisors Llc | 1.49% | 1.90M | $1.83M |
| 8 | Geode Capital Management, LLC | 0.99% | 1.27M | $1.22M |
| 9 | Acadian Asset Management. LLC | 0.83% | 1.06M | $1.02M |
| 10 | Clearstead Advisors, LLC | 0.70% | 892.79K | $862.43K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NAUT
Nautilus found 130 forms of a protein linked to Alzheimer’s. Some appeared in just 0.1% of samples. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPUDVheXJlUy04OHRfbUVWNFE1WFAzS2pRZUxnN2NaWXBDOTFxcHZLZUZOcU9tTmQ2T1o1OHJsRXlvbWhGR0VDS1Nwc0MwTjcxeDJSSllrdGI1dkRWY19uV1hRVzhkYzFlb3NKNTl1cWlrV2NvbkN6Z013ZUNGYi1WLUpIc0Q2NEw5cXZfZG…
$NAUT stock is down 25% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNSkZiSElHVG5nWWN3R2VERU5wdjdVbVhDSUd1ZTlrNElLYWlrckl5QjJseFotQkpraVhPX05Hb0FabEszT1NEVFpxUlhLR21jNEZ2ekNWcm9pX2RUNEl3OWlDVnZuUFB6blIzVFRSU1VQMkJfWW1RbFFtcGowZXFTMUp6MlZFZnV3b0F1az…
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxQMmRMYjRMeGktTkxNcVREX2NoejM1UEQ1X1RaN2VubG5TQjhBay1feHJ2OG9NYzd3cG9wQkNTMmVoSDZzaFZ2cHhudnBEN0psRE41eV9taFM1Uks4cGF2eW1TcnA1MmRPYnV3Nm9nQVdaa3UwZ0h5dHYzWEZHV2lSdGh3eDRMQ0lvY19sUF…
NAUT Stock Price and Chart — NASDAQ:NAUT - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE4yTFRZV25WbVN4Mk1xQ2ZBQUZRNWozUTM2NUVhQXprREZDcjBfXzZYeW1TTjZ0cHBQdjgwVXZ6MTh6MUpMZWZzSXpQcDhwU256UDZOOENkZHJmMmRh?oc=5" target="_blank">NAUT Stock Price and Chart — NASDAQ:NAUT</a…
Nautilus Biotechnology: A Contrarian Proteoformics Play After Recent Pullback (NAUT) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQMUgyVWtkU00wS2Zfc1lHVWltMkxwNDQyRGpqWlRFQldCNDRfaUlpaEpGVzBadHlSalRQd0FIVE0tZHpFVmx3VkFXY1ktSjNwZHhDZDVsSmIzZnUzbDVvOG5DUlhQT1Q1M0tiWWR3Q1JSNll4REN1WW1KemUyUEdLemdFQnkzZ1FXbTJXME…
NAUT - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5GSUljY1oybDFWTUpNQ1lNbXlISGIxUDJJbllKNzlJN1Z4UDI2ejJMTGJBMVVua0RjTEtySVlRY0hnU1d2VGc?oc=5" target="_blank">NAUT</a> <font color="#6f6f6f">Finviz</font>…
NAUT — Frequently Asked Questions
What is the current share price of Nautilus Biotechnology, Inc. (NAUT)?
As of 2026-09-19 21:16 PDT, Nautilus Biotechnology, Inc. (NAUT) trades at $0.93 on NasdaqCM. Its 52-week range is $0.64 to $3.95.
What is the market capitalisation of NAUT?
Nautilus Biotechnology, Inc. (NAUT) has a market capitalisation of $118.18M on NasdaqCM.
What is the P/E ratio of NAUT?
NAUT trades at a trailing price-to-earnings (P/E) ratio of -2.07. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of NAUT?
NAUT has a return on equity (ROE) of -36.21%.
Is NAUT a good stock to buy?
This page provides a data-driven analysis of Nautilus Biotechnology, Inc. (NAUT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.